{
  "id": "6278dc0c56bf9aee6f000010",
  "type": "list",
  "question": "Which biomarkers are currently used for Duchenne Muscular Dystrophy?",
  "ideal_answer": "MRI measurements can be used as biomarkers of disease severity in ambulant patients with DMD. malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26091074",
    "http://www.ncbi.nlm.nih.gov/pubmed/30499689",
    "http://www.ncbi.nlm.nih.gov/pubmed/28252048",
    "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
    "http://www.ncbi.nlm.nih.gov/pubmed/24813925",
    "http://www.ncbi.nlm.nih.gov/pubmed/28821969",
    "http://www.ncbi.nlm.nih.gov/pubmed/26963343",
    "http://www.ncbi.nlm.nih.gov/pubmed/31892637",
    "http://www.ncbi.nlm.nih.gov/pubmed/34439489",
    "http://www.ncbi.nlm.nih.gov/pubmed/32791870",
    "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
    "http://www.ncbi.nlm.nih.gov/pubmed/23945935",
    "http://www.ncbi.nlm.nih.gov/pubmed/27778157",
    "http://www.ncbi.nlm.nih.gov/pubmed/27979502",
    "http://www.ncbi.nlm.nih.gov/pubmed/32390640",
    "http://www.ncbi.nlm.nih.gov/pubmed/21479190",
    "http://www.ncbi.nlm.nih.gov/pubmed/25150707",
    "http://www.ncbi.nlm.nih.gov/pubmed/27854211",
    "http://www.ncbi.nlm.nih.gov/pubmed/32695843",
    "http://www.ncbi.nlm.nih.gov/pubmed/31881125",
    "http://www.ncbi.nlm.nih.gov/pubmed/29554116",
    "http://www.ncbi.nlm.nih.gov/pubmed/31838454",
    "http://www.ncbi.nlm.nih.gov/pubmed/32476037",
    "http://www.ncbi.nlm.nih.gov/pubmed/24460924"
  ],
  "snippets": [
    {
      "text": "MRI measurements can be used as biomarkers of disease severity in ambulant patients with DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31892637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31881125",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aim: Evaluate the utility of glutamate dehydrogenase (GLDH) and cardiac troponin I\u00a0as safety biomarkers, and creatine kinase\u00a0and muscle injury panel\u00a0as muscle health biomarkers in Duchenne muscular dystrop",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695843",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Extracellular microRNAs (miRNAs) are promising biomarkers of the inherited muscle wasting condition Duchenne muscular dystrophy, as they allow non-invasive monitoring of either disease progression or response to therapy. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945935",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32476037",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: The diagnosis of Duchenne Muscular Dystrophy (DMD) currently depends on non-specific measures such as Creatine kinase (CK)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31838454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963343",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aim: Evaluate the utility of glutamate dehydrogenase (GLDH) and cardiac troponin I\u00a0as safety biomarkers, and creatine kinase\u00a0and muscle injury panel\u00a0as muscle health biomarkers in Duchenne muscular dystrophy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results for five leading candidate protein biomarkers (Pgam1, Tnni3, Camk2b, Cycs and Adamts5) were validated by ELISA in the mouse samples",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s observed. Therefore, three microRNAs (miRNAs), miR-1, miR-133a, and miR-206, were previously reported as alternative biomarkers for duchenne muscular dyst",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150707",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Results support the use of GLDH as a specific biomarker for liver injury in patients with Duchenne muscular dystrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Creatine kinase (CK) is generally used as a blood-based biomarker for muscular disease including DMD, but it is not always reliable since it is easily affected by stress to the body, such as exercise.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ", albumin Cys34 undergoes thiol oxidation and these changes correlate with levels of protein thiol oxidation and damage of the dystrophic muscles. A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34439489",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that plasma albumin oxidation reflects muscle dystropathology, as increased after exercise and decreased after taurine treatment of mdx mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34439489",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These data support the use of albumin thiol oxidation as a blood biomarker of dystropathology to assist with advancing clinical development of therapies for DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34439489",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among a selected set of potential biomarkers for cardiomyopathy (MMP9, BNP, GAL3, CRP, LEP, TNC, TLR4 and ST2) we validated ST2 as significantly elevated in the serum of DMD cardiomyopathy group (35,798\u00a0\u00b1\u00a04884\u00a0pg/mL) compared to normal controls (9940\u00a0\u00b1\u00a02680\u00a0pg/mL; p\u00a0<\u00a00.01; n\u00a0=\u00a06).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Matrix metallopeptidase 9 (MMP9) levels were found significantly increased in both DMD groups compared to controls (p\u00a0<\u00a00.01).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased ST2 levels were found in serum of DMD subjects compared to healthy volunteers and further elevated in DMD subjects with cardiomyopathy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821969",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Extracellular dystrophy-associated miRNAs (dystromiRs) show dynamic patterns of expression that mirror the progression of muscle pathology in mdx mice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945935",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "xpression of the myogenic miRNA, miR-206 and the myogenic transcription factor myogenin in the tibialis anterior muscle were found to positively correlate with serum dystromiR levels, suggesting that extracellular miRNAs are indicators of the regenerative status of the musculature.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945935",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our data revealed that miR-499 was significantly upregulated in all DMD patients, and true carriers (mothers), while 78 % of potential carriers (sisters) exhibited high levels of this miRNA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31838454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similarly, miR-103a-3p showed an increase in the patients' families although to a lesser extent. On the other hand, miR-206 and miR-191-5p were significantly downregulated in the majority of the DMD patients and the tested female family members. MicroRNA miR-103a-5p and miR-208a followed a comparable trend in patients and mothers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31838454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OPN is a promising biomarker for muscle regeneration in dystrophic dogs and can be applicable to boys with Duchenne muscular dystrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963343",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The serum OPN level was significantly correlated with the phenotypic severity of dystrophic dogs at the period corresponding to the onset of muscle weakness, whereas other serum markers including creatine kinase were not. Immunohistologically, OPN was up-regulated in infiltrating macrophages and developmental myosin heavy chain-positive regenerating muscle fibers in the dystrophic dogs, whereas serum OPN was highly elevated. OPN expression was also observed during the synergic muscle regeneration process induced by cardiotoxin injection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963343",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were very good inverse correlations between the levels of these miRNAs, especially miR-206, and functional performances: high levels corresponded to low muscle strength, muscle function, and quality of life. Moreover, by receiver operating characteristic curves analyses, we revealed that these miRNAs, especially miR-206, were able to discriminate DMD from controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "miR-206 and other muscle-specific miRNAs in serum are useful for monitoring the DMD pathological progression, and hence as potential non-invasive biomarkers for the disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "miR-206 and other muscle-specific miRNAs are useful as non-invasive biomarkers for DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, ADAMTS5 was found to be significantly elevated in human DMD patient serum. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging MRI biomarkers of myocardial function and structure include the estimation of rotational mechanics and regional strain using MRI tagging; T1-mapping; and T2-mapping, a marker of inflammation, edema and fat. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30499689",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Significant correlations were found between all qMR and functional measures. Vastus lateralis qMR measures correlated most strongly to functional endpoints (|\u03c1| = 0.68-0.78), although measures in other rapidly progressing muscles including the biceps femoris (|\u03c1| = 0.63-0.73) and peroneals (|\u03c1| = 0.59-0.72) also showed strong correlations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Quantitative MR biomarkers were excellent indicators of loss of functional ability and correlated with qualitative measures of function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results show that the serum levels of miR-30c and miR-181a increased 7- and 6-fold respectively in DMD patients (n\u2009=\u200921, 2-14 years, ambulant), and 7-fold in BMD patients (n\u2009=\u20095, 9-15 years) compared to controls (n\u2009=\u200922, 2-14 years).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27979502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, there was a trend towards higher levels of miR-30c in DMD patients with better preserved motor function according to various motor scales and timed tests. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27979502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We propose miR-30c and miR-181a as reliable serum diagnostic biomarkers for DMD and BMD and miR-30c as a potential novel biomarker to assess disease severity in DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27979502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "highlights novel mdx biomarkers (GITR, MYBPC1, HSP60, SIRT2, SMAD3, CNTN1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28252048",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, the five TFs ZNF362, ATAT1, SPI1, TCF12 and ABCF2, as well as the eight miRNAs miR-124a, miR-200b/200c/429, miR-19a/b, miR-23a/b, miR-182, miR-144, miR-498 and miR-18a/b were identified as playing crucial roles in the molecular pathogenesis of DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32791870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "erein we examined the potential applicability of serum levels of matrix metalloproteinase 9 and matrix metalloproteinase 2, tissue inhibitor of metalloproteinases 1, myostatin (GDF-8) and follistatin (FSTN) as non-invasive biomarkers to distinguish between DMD steroid na\u00efve patients and healthy controls of similar age and also for carrier detection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091074",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our data suggest that serum levels of MMP-9, GDF-8 and FSTN are useful to discriminate DMD from controls (p < 0.05), to correlate with some neuromuscular assessments for DMD, and also to differentiate between Becker muscular dystrophy (BMD) and Limb-girdle muscular dystrophy (LGMD) patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091074",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "carbonic anhydrase 3, microtubule associated protein 4 and collagen type I alpha 1 chain decline rather constantly over time, myosin light chain 3, electron transfer flavoprotein A, troponin T, malate dehydrogenase 2, lactate dehydrogenase B and nestin plateaus in early teens. Electron transfer flavoprotein A, correlates with the outcome of 6-minutes-walking-test whereas malate dehydrogenase 2 together with myosin light chain 3, carbonic anhydrase 3 and nestin correlate with respiratory capacity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32390640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " a component of the DAG complex as a potential serum biomarker in DMD. Such a serum measure could be further developed as a tool to help reflect overall muscle DAG complex expression or stability.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27854211",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "MRI, fat fraction MRI, MRI mean T2, qMR biomarkers, malate dehydrogenase 2, albumin thiol oxidation, myostatin, Interleukin 1 Receptor-Like 1 Protein, ST2, Extracellular dystrophy-associated miRNAs, dystromiRs, Troponin I, Creatine kinase, CK, miR-499, miR-191-5p, miR-223, miR-208a, miR-206, miR-103a-5p, miR-103a-3p, Serum Ostepontin, OPN, Ostepontin, Serum OPN, Pgam1, Tnni3, Camk2b, Cycs, Adamts5, miR-30c, miR-181a, CNTN1, SMAD3, SIRT2, HSP60, MYBPC1, GITR, Titin, miR-18a/b, miR-498, miR-144, miR-182, miR-23a/b, miR-19a/b, miR-200b/200c/429, miR-124a, MMP-9, GDF-8, FSTN, a component of the DAG complex, aDG-N"
}